Efficacy and Safety of Pirfenidone Treatment in HPS-ILD

PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Hermansky Pudlak SyndromeInterstitial Lung Disease
Interventions
DRUG

Pirfenidone

Pirfenidone will be titrated over 14 days, as tolerated, to the full dose of 2403 mg per day, as follows: Days 1 - 7: one capsule TID; Days 8 - 14: two capsules TID; Days 15 to week 52: three capsules TID. Dose may be reduced to manage an adverse event.

Trial Locations (2)

19107

Thomas Jefferson University, Philadelphia

00680

Mayaguez Medical Center, Mayagüez

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Jesse Roman

OTHER

NCT04193592 - Efficacy and Safety of Pirfenidone Treatment in HPS-ILD | Biotech Hunter | Biotech Hunter